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Long-term follow-up of Philadelphia chromosome-positive (Ph+)
chronic myeloid leukaemia (CML) in children and adolescents
managed at a single institution over a 20-year period
Chronic myeloid leukaemia (CML) rarely affects children.
Allogeneic haematopoietic stem cell transplant (allo-HSCT) is
feasible only for a minority of patients. Although clinical
research on alpha-interferon (IFN) in CML began two decades
ago, the few published series of childhood CML reported
cytogenetic response (CyR) rates but no long-term treatment
results (Dow et al, 1991; Millot et al, 2002). Recently, imatinib
has shown efficacy in Philadelphia chromosome-positive (Ph+)
CML patients, also in those previously treated with IFN
(O’Brien et al, 2003; Champagne et al, 2004; Kantarjian et al,
2004).
The treatment results, updated at December 2004, of 30 Ph+
CML children and adolescents (16 males and 14 females;
median age of 12Æ17 years), diagnosed at our Institution
between June 1980 and September 2001, are reported (Table I).
Allo-HSCT was performed in patients with a matched related
donor (MRD), while those lacking a MRD received different
treatments. Before 1989, patients without a MRD were treated
with hydroxyurea; during that period, two patients underwent
an autologous stem cell transplant (ASCT) and then low-dose
IFN. Starting from 1990, 19 patients received IFN at a dosage of
2Æ5–9 MU/day (median 6 MU/day). When patients did not
respond to IFN, a search was started for a human leucocyte
antigen (HLA)-matched unrelated donor (MUD) and, from
1995, for umbilical cord blood (UCB) stem cells. Recently,
patients who failed IFN were treated with imatinib.
A CyR was achieved in 11 of 17 evaluable patients treated
with IFN (65%): complete (CCyR) in four and partial in seven;
the median time to achieve maximal CyR was 12 months
(range: 4–96 months). The CCyR persisted in three of the four
complete responders, in whom the BCR-ABL transcript
subsequently disappeared. Of the 14 patients who failed IFN
treatment, five underwent allo-HSCT, while five were switched
to imatinib and obtained a CCyR.
The projected 8-year survival of all patients treated with
IFN was 63% [95% confidence interval (CI): 39Æ6–87Æ3];
censoring patients at the start of imatinib or at the date of
allo-HSCT, the projected 8-year survival was 62% (95% CI:
31Æ6–92Æ7).
Thirteen patients underwent an allo-HSCT, seven of them
had previously received IFN and one had also received an
ASCT. Four patients that were allografted from a MRD are
alive with no evidence of the BCR-ABL transcript, two of them
after IFN dose escalation combined with a single donor
lymphocyte infusion (DLI) because of disease recurrence.
Three MUD allografted patients and one patient submitted
to a mismatched related donor transplant are alive with no
evidence of the BCR-ABL transcript. The projected 8-year
survival from the date of allo-HSCT for all transplanted
patients, independent of the type of transplant, disease status,
interval from diagnosis to transplant and prior therapy was
61% (95% CI: 33Æ5–87Æ7).
In our experience, which reflects the therapeutic changes
that have occurred over the two last decades, the survival
probability of patients treated with high-dose IFN is similar
to that of patients submitted to allo-HSCT. The prolonged
use of IFN did not impair the outcome of allo-HSCT and
induced a CcyR, even after 8 years. Furthermore, it led to a
BCR-ABL transcript disappearance in three of four CCy
responders to high-dose IFN and in two children who had
relapsed after transplant and subsequently treated with IFN
combined with DLI. Disappearance of the BCR-ABL tran-
script after IFN has been recorded in adults, also in those
who relapsed after allo-HSCT (Steegmann et al, 1999), but so
far not in children. Furthermore, in agreement with reported
data (Champagne et al, 2004; Kantarjian et al, 2004) imatinib
induced CCyR in our children that had previously been
treated with IFN.
In conclusion, our results indicate that IFN may still have a
role in the future treatment strategies for childhood CML,
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